NO322892B1 - Galantaminhydrobromidtablett og fremgangsmate for fremstilling av denne. - Google Patents
Galantaminhydrobromidtablett og fremgangsmate for fremstilling av denne. Download PDFInfo
- Publication number
- NO322892B1 NO322892B1 NO19985815A NO985815A NO322892B1 NO 322892 B1 NO322892 B1 NO 322892B1 NO 19985815 A NO19985815 A NO 19985815A NO 985815 A NO985815 A NO 985815A NO 322892 B1 NO322892 B1 NO 322892B1
- Authority
- NO
- Norway
- Prior art keywords
- tablet
- lubricant
- tablet according
- film
- galantamine hydrobromide
- Prior art date
Links
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 title claims description 22
- 229960002024 galantamine hydrobromide Drugs 0.000 title claims description 19
- 238000000034 method Methods 0.000 title description 4
- 239000000314 lubricant Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 10
- 239000007888 film coating Substances 0.000 claims description 10
- 238000009501 film coating Methods 0.000 claims description 10
- 229960001021 lactose monohydrate Drugs 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000011363 dried mixture Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000012749 thinning agent Substances 0.000 claims description 3
- 238000007580 dry-mixing Methods 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 45
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 26
- 238000004090 dissolution Methods 0.000 description 16
- 229960003980 galantamine Drugs 0.000 description 13
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 239000007916 tablet composition Substances 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000007941 film coated tablet Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- DITOENWBJBNZSL-UHFFFAOYSA-N O-methyl-hippeastrine Natural products C1=C2C3C4N(C)CCC4=CC(OC)C3OC(=O)C2=CC2=C1OCO2 DITOENWBJBNZSL-UHFFFAOYSA-N 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 150000003797 alkaloid derivatives Chemical group 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- -1 "macrogol" 6000 Chemical compound 0.000 description 1
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- HHEMQQWULBJWLK-UHFFFAOYSA-N 1h-1-benzazepin-6-ol Chemical compound N1C=CC=CC2=C1C=CC=C2O HHEMQQWULBJWLK-UHFFFAOYSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000001375 Facial Neuralgia Diseases 0.000 description 1
- 241000234271 Galanthus Species 0.000 description 1
- 241001502107 Galanthus alpinus Species 0.000 description 1
- 241000234283 Galanthus nivalis Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101100532451 Rattus norvegicus Slc22a17 gene Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 208000012790 cranial neuralgia Diseases 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000012313 reversal agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96201676 | 1996-06-14 | ||
| PCT/EP1997/002986 WO1997047304A1 (en) | 1996-06-14 | 1997-06-06 | Fast-dissolving galanthamine hydrobromide tablet |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO985815D0 NO985815D0 (no) | 1998-12-11 |
| NO985815L NO985815L (no) | 1998-12-11 |
| NO322892B1 true NO322892B1 (no) | 2006-12-18 |
Family
ID=8224084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19985815A NO322892B1 (no) | 1996-06-14 | 1998-12-11 | Galantaminhydrobromidtablett og fremgangsmate for fremstilling av denne. |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US6099863A (xx) |
| EP (1) | EP0915701B1 (xx) |
| JP (1) | JP4172820B2 (xx) |
| KR (1) | KR100358676B1 (xx) |
| CN (1) | CN1102390C (xx) |
| AR (2) | AR008237A1 (xx) |
| AT (1) | ATE285777T1 (xx) |
| AU (1) | AU726212B2 (xx) |
| BG (1) | BG64168B1 (xx) |
| BR (1) | BR9709729A (xx) |
| CA (1) | CA2257431C (xx) |
| CZ (1) | CZ295226B6 (xx) |
| DE (1) | DE69732113T2 (xx) |
| DK (1) | DK0915701T3 (xx) |
| EA (1) | EA001193B1 (xx) |
| EE (1) | EE03337B1 (xx) |
| ES (1) | ES2235234T3 (xx) |
| HK (1) | HK1019703A1 (xx) |
| HR (1) | HRP970321B1 (xx) |
| ID (1) | ID17088A (xx) |
| IL (1) | IL127519A (xx) |
| MY (1) | MY121669A (xx) |
| NO (1) | NO322892B1 (xx) |
| NZ (1) | NZ333280A (xx) |
| PL (1) | PL189329B1 (xx) |
| PT (1) | PT915701E (xx) |
| SI (1) | SI0915701T1 (xx) |
| SK (1) | SK284620B6 (xx) |
| TR (1) | TR199802592T2 (xx) |
| TW (1) | TW506836B (xx) |
| UA (1) | UA62930C2 (xx) |
| WO (1) | WO1997047304A1 (xx) |
| ZA (1) | ZA975281B (xx) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440457B1 (en) * | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| DE69912311T2 (de) * | 1998-12-24 | 2004-07-29 | Janssen Pharmaceutica N.V. | Galantamin-zusammensetzung mit gesteuerter freisetzung |
| US20050063998A1 (en) * | 1999-10-26 | 2005-03-24 | Francois Marc Karel Jozef | Oral solution containing galantamine and a sweetening agent |
| US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| AU2001257022B2 (en) * | 2000-04-13 | 2005-02-03 | Mayo Foundation For Medical Education And Research | Abeta 42 lowering agents |
| SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| US6500454B1 (en) * | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
| DE10235556A1 (de) * | 2002-08-03 | 2004-02-19 | Hf Arzneimittelforschung Gmbh | Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums |
| US20040097484A1 (en) * | 2002-11-14 | 2004-05-20 | Marc Cantillion | Once a day galantamine pharmaceutical compositions and methods of use |
| EP3473251B1 (en) * | 2002-12-20 | 2023-12-13 | NicoNovum AB | A nicotine-cellulose combination |
| US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS |
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| EP2792363B1 (en) * | 2003-08-26 | 2016-06-29 | Shire Biopharmaceuticals Holdings Ireland Limited | Pharmaceutical formulation comprising lanthanum compounds |
| US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| WO2005051489A2 (en) * | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | Fast dissolving solid oral dosage forms of galanthamine |
| EP2340813A1 (en) * | 2003-12-31 | 2011-07-06 | Actavis Group PTC ehf. | Solid dosage formulations of galantamine |
| US20050191349A1 (en) * | 2003-12-31 | 2005-09-01 | Garth Boehm | Galantamine formulations |
| CA2552114A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| BRPI0514303A (pt) * | 2004-08-11 | 2008-06-10 | Myriad Genetics Inc | composição farmacêutica e método para tratar distúrbios neurodegenerativos |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US7888346B2 (en) * | 2004-09-24 | 2011-02-15 | Universtiy of Maryland, Baltimore | Method of treating organophosphorous poisoning |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| NZ709754A (en) | 2004-10-21 | 2017-02-24 | Adare Pharmaceuticals Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| KR20070084455A (ko) * | 2004-11-23 | 2007-08-24 | 워너-램버트 캄파니 엘엘씨 | 지질혈증 치료용 ｈｍｇ ｃｏ-ａ 환원효소 억제제로서의7-(2ｈ-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체 |
| US20080145422A1 (en) * | 2005-02-10 | 2008-06-19 | Roxane Laboratories, Inc. | Galantamine tablet formulation |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| GB0516604D0 (en) * | 2005-08-12 | 2005-09-21 | Sandoz Ag | Rapidly dispersing/disintegrating compositions |
| US8168219B2 (en) * | 2005-11-30 | 2012-05-01 | Isp Investments Inc. | Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability |
| WO2007104573A2 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
| WO2007121537A1 (en) * | 2006-04-26 | 2007-11-01 | Alphapharm Pty Ltd | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix |
| GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| WO2008008120A1 (en) * | 2006-07-14 | 2008-01-17 | Fmc Corporation | Solid form |
| CN100438917C (zh) * | 2006-07-20 | 2008-12-03 | 山东聊城阿华制药有限公司 | 一种微晶纤维素乳糖的制备方法 |
| WO2008062426A2 (en) * | 2006-08-02 | 2008-05-29 | Emcure Pharmaceuticals Limited | Formulation of benzazepine derivatives |
| BRPI0718437A2 (pt) | 2006-10-27 | 2013-11-19 | Medivation Neurology Inc | Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil |
| US20080311162A1 (en) * | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
| PE20091156A1 (es) * | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
| EP2116232B1 (de) | 2008-05-09 | 2012-02-15 | Ratiopharm GmbH | Galanthaminhaltiges Arzneimittel mit kontrollierter Freisetzung |
| MX2012006240A (es) | 2009-12-02 | 2012-10-03 | Aptalis Pharma Ltd | Microcapsulas de fexofenadina y composiciones que contienen las mismas. |
| WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
| JP5656258B2 (ja) * | 2011-03-09 | 2015-01-21 | 塩野義製薬株式会社 | ガランタミンを含有する口腔内崩壊錠剤 |
| US10357486B2 (en) | 2013-08-16 | 2019-07-23 | Universiteit Maastricht | Treatment of cognitive impairment with PDE4 inhibitor |
| CN106822008A (zh) * | 2017-01-11 | 2017-06-13 | 江苏艾兰得营养品有限公司 | 一种维生素d速溶制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3506276C1 (de) * | 1985-02-22 | 1986-04-24 | Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring | Direkttablettiermittel |
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| US6150354A (en) * | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| ATE183084T1 (de) * | 1991-05-14 | 1999-08-15 | Ernir Snorrason | Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
-
1997
- 1997-05-19 TW TW086106622A patent/TW506836B/zh not_active IP Right Cessation
- 1997-06-06 WO PCT/EP1997/002986 patent/WO1997047304A1/en active IP Right Grant
- 1997-06-06 TR TR1998/02592T patent/TR199802592T2/xx unknown
- 1997-06-06 EP EP97927159A patent/EP0915701B1/en not_active Expired - Lifetime
- 1997-06-06 CN CN97195512A patent/CN1102390C/zh not_active Expired - Lifetime
- 1997-06-06 DE DE69732113T patent/DE69732113T2/de not_active Expired - Lifetime
- 1997-06-06 CZ CZ19984034A patent/CZ295226B6/cs not_active IP Right Cessation
- 1997-06-06 SI SI9730690T patent/SI0915701T1/xx unknown
- 1997-06-06 AU AU31743/97A patent/AU726212B2/en not_active Expired
- 1997-06-06 US US09/202,187 patent/US6099863A/en not_active Expired - Lifetime
- 1997-06-06 NZ NZ333280A patent/NZ333280A/en not_active IP Right Cessation
- 1997-06-06 PL PL97330431A patent/PL189329B1/pl unknown
- 1997-06-06 KR KR10-1998-0709401A patent/KR100358676B1/ko not_active IP Right Cessation
- 1997-06-06 CA CA002257431A patent/CA2257431C/en not_active Expired - Lifetime
- 1997-06-06 SK SK1696-98A patent/SK284620B6/sk not_active IP Right Cessation
- 1997-06-06 BR BR9709729A patent/BR9709729A/pt not_active IP Right Cessation
- 1997-06-06 PT PT97927159T patent/PT915701E/pt unknown
- 1997-06-06 AT AT97927159T patent/ATE285777T1/de active
- 1997-06-06 DK DK97927159T patent/DK0915701T3/da active
- 1997-06-06 EE EE9800429A patent/EE03337B1/xx unknown
- 1997-06-06 UA UA98126372A patent/UA62930C2/uk unknown
- 1997-06-06 JP JP50118198A patent/JP4172820B2/ja not_active Expired - Lifetime
- 1997-06-06 IL IL12751997A patent/IL127519A/en not_active IP Right Cessation
- 1997-06-06 EA EA199900026A patent/EA001193B1/ru not_active IP Right Cessation
- 1997-06-06 ES ES97927159T patent/ES2235234T3/es not_active Expired - Lifetime
- 1997-06-11 HR HR970321A patent/HRP970321B1/xx not_active IP Right Cessation
- 1997-06-12 MY MYPI97002621A patent/MY121669A/en unknown
- 1997-06-13 AR ARP970102615A patent/AR008237A1/es active IP Right Grant
- 1997-06-13 ID IDP972025A patent/ID17088A/id unknown
- 1997-06-13 ZA ZA975281A patent/ZA975281B/xx unknown
-
1998
- 1998-12-04 BG BG102991A patent/BG64168B1/bg unknown
- 1998-12-11 NO NO19985815A patent/NO322892B1/no not_active IP Right Cessation
-
1999
- 1999-07-10 HK HK99102948A patent/HK1019703A1/xx not_active IP Right Cessation
-
2000
- 2000-06-01 US US09/585,122 patent/US6358527B1/en not_active Expired - Lifetime
-
2008
- 2008-11-25 AR ARP080105111A patent/AR070670A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO322892B1 (no) | Galantaminhydrobromidtablett og fremgangsmate for fremstilling av denne. | |
| US6673369B2 (en) | Controlled release formulation | |
| US20100272801A1 (en) | Pharmaceutical compositions of amlodipine and valsartan | |
| KR20150002550A (ko) | 타다라필 및 탐수로신을 함유하는 약학적 캡슐 복합 제제 | |
| US20080227836A1 (en) | Stable Solid Oral Dosage Forms of Valsartan | |
| WO2012077968A2 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
| CA2180703A1 (en) | Fast-dissolving galanthamine hydrobromide tablet | |
| WO2007043061A1 (en) | Anti-malarial combination and methods of formulation | |
| EP2243468A1 (en) | Orally Disintegrating Dimebolin Compositions | |
| US20050053657A1 (en) | Controlled release formulation of clarithromycin or tinidazol | |
| US20050142193A1 (en) | Galantamine formulations | |
| Kulkarni et al. | formulation and evaluation of immediate release tablet of Valsartan | |
| US20160317662A1 (en) | Stable oral pharmaceutical composition | |
| HU226132B1 (en) | Fast-dissolving galanthamine hydrobromide tablet | |
| EP2736498B1 (en) | Prolonged release pharmaceutical composition comprising galantamine and method for the preparation thereof | |
| US20040192706A1 (en) | Method and compositions for treating anxiety | |
| EP1713451A1 (en) | Solid dosage formulations of galanthamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |